Results 101 to 110 of about 137,923 (290)

Diagnosis validity of AgNOR staining for differentaing non-Hodgkin lymphoma from reactive hyperplasia

مجله دانشگاه علوم پزشکی گرگان, 2005
Background&Objective: There are different methods including H&E, imonhistochemstry, flu cytometry, AgNOR staining for differentiation reactive hyperplasia from lymphoma.
Zh.Torabizade (MD), F.Naghshvar (MD), O.Emadian (MD)   +2 more
doaj  

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Non-Hogkins lymphoma ′masquerading′ as pott′s disease in a 13-year old boy: A case report

Sahel Medical Journal, 2010
Lymphomas are malignant neoplasms of the lymphoid lineage which are broadly classified as either Hodgkin disease or as non-Hodgkin lymphoma (NHL).
O A Adegboye
doaj  

Primary Dural Lymphoma: Clinical Cases and Literature Review

Case Reports in Medicine, 2020
Primary dural lymphoma (PDL) is an extranodal non-Hodgkin lymphoma that accounts for less than 1% of all central nervous system lymphomas. Primary dural lymphoma grows from the dura mater, and it is often diagnosed as meningioma or acute subdural ...
M. Dobran, R. Paracino, F. Mancini, D. Nasi   +3 more
doaj   +1 more source

LARGE EXTRANODAL NON HODGKIN'S LYMPHOMA OF THE PARAPHARYNGEAL SPACE [PDF]

, 2013
Of all head and neck tumors, 0.5% to 0.8% of them are localized in the parapharyngeal space. Non-Hodgkin’s lymphomas in this site are extremely rare. There are described in literature as either isolated cases or small series of tumors of that space.
Aleric, Zorica, Bauer, Vladimir
core   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke, Jeelall, Yogesh S., Wang, James Q.   +2 more
core   +1 more source

Staging Non-Hodgkin Lymphoma [PDF]

CA: A Cancer Journal for Clinicians, 2005
Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification.
openaire   +2 more sources

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

Immune Thrombocytopenia in a Child with T Cell Lymphoblastic Lymphoma

Case Reports in Hematology, 2016
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma.
Kayo Tokeji, Sachi Sakaguchi, Tomoko Kurimoto, Junya Fujimura, Toshiaki Shimizu   +4 more
doaj   +1 more source

Immunosenescence and lymphomagenesis [PDF]

, 2018
One of the most important determinants of aging-related changes is a complex biological process emerged recently and called \u201cimmunosenescence\u201d.
A Beheshti, A Engert, A Grignolio, A Nicolae, A Rosenwald, A Tucci, AM Evens, BB Hart, BF Skinnider, BK Edwards, BO Nilsson, C Caruso, C Castelo-Branco, C Falandry, C Falandry, C Franceschi, C Franceschi, C Kenis, C Sarkozy, C Sarkozy, C Thieblemont, CC Porter, CM Koebel, D Aldinucci, D Hanahan, D Zhou, DB Palmer, DM Parkin, DP Shanley, E Campo, E Cesarman, E Zucca, F Suarez, FL Erdkamp, FT Hakim, G Accardi, G Genovese, G Lenz, G Pawelec, GM Clifford, H Wildiers, I Schwering, J Campisi, J Wang, JJ Castillo, L Malaguarnera, LM Morton, M Goto, M Martelli, M Weltevrede, Marco Santoro, Mariasanta Napolitano, Melania Carlisi, N Asano, NS Wong, O Balague Ponz, P Skrabek, PJ Linton, PR Taylor, PR Walker, R Kim, RF Jarrett, RL Bowman, RR Montgomery, S Dubois, S Joos, S Mareschal, S Mathas, S Mathas, S Puvvada, Salvatrice Mancuso, Sergio Siragusa, SH Swerdlow, Simona Raso, SJ Morrison, SJ Proctor, SL Glaser, SR Gordon, SR Hadrup, T Finkel, T Fulop, T Fulop, T Fülöp, T Fülöp, T Fülöp, T Ishida, T Wada, W Drew, W Klapper, Z Ju, Z Song   +90 more
core   +1 more source